David Pascoe
David Pascoe started the Rosacea Support Group in October 1998.

Journey Medical Corporation are readying to release their Phase 3 clinical trial data for DFD-29, their delayed release 40mg minocycline treatment for rosacea. Targeted as a competitor to Galderma’s successful doxycycline based Oracea, the yet to be named DFD-29 is expected to release clinical data that will demonstrate superior treatment results. According to Journey Medical’s […]

Galderma has announced that Epsolay has been approved by the FDA for treating rosacea. Epsolay is a proprietary cream formulation of benzoyl peroxide, 5%, designated for the treatment of inflammatory lesions of rosacea in adults. In July 2021 Galderma announced an exclusive 5 year deal to market Epsolay in the US. The creators of Epsolay […]

In 2017, the FDA approved the extended release formulation of minocycline, known as Minolira, for the treatment of severe acne vulgaris. The modified release formulation of doxycycline known as Oracea, was approved for the treatment of rosacea in 2006. As minocycline and doxycycline are related tetracyclines, Minolira may offer rosacea sufferers another rosacea treatment option, […]